Abstract:The classic Bcr-Abl negative myeloproliferative disorders (MPDs) comprise polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF). They are considered clonal stem cell disorders. Recently two acquired somatic mutations JAK2V617F and MPLW515L/K have been identified to play an important role in pathogenisis of MPDs. JAK2V617F was detected in almost all PV and nearly 50% in ET and IMF, and the MPLW515L/K mutation occured in only 1% and 4% in ET and IMF respectively. However it is interesting that there are some patients with slightly increased blood cells did not meet the criteria of PV and ET clinically. These early prefibrotic stages of MPDs are overlooked by both the Polycythemia Vera Study Group (PVSG) and the 2001 WHO criteria for the diagnosis of PV, ET and IMF. In order to investigate the prevalence of JAK2V617F and MPLW515L/K mutation in patients with early MPDs without a secondary cause, genomic DNA from bone marrow or blood mononuclear cells of 30 patients with early MPDs was screened by allele specific polymerase chain reaction (AS-PCR) for JAK2V617F and MPLW515L/K mutations and the history of thrombosis was assessed retrospectively by using patient files. Results showed that 14 out of 30 patients (46.7%) were positive for the JAK2V617F mutation, and none of them had the MPLW515L/K. Of the 14 patients with JAK2V617F mutation, a history of thrombosis was comfirmed in 5 patients(35.7%), while none of 16 patients with WT JAK2 had the thrombosis history. The average age of patients with the JAK2V617F mutation exceeded the patients with wild type JAK2(P<0.05), whereas there is no statistical significance on sexual Athe counts of white cell and the occurance of complications (thrombosis) between the patients with and without the JAK2V617F mutation. All the patients have been followed up since onset and 22 patients have available results. Among them, 12 patients with the burden of JAK2V617F turned out to be MPDs, however only 1 out of 10 patients without this mutation also evolved to MPDs. Our results suggest that JAK2V617F mutation can occur in a certain percentage of these early stage of MPDs patients and has help to diagnose early MPDs. Because these patients might have a high rate of complications, proper treatment of the MPD including aspirin and/or cytoreductive therapy is recommended in latent MPDs patients associated with the JAK2V617F mutation.

Research Progress of Myeloproliferative Disorders: Several Clinical Problems Post the JAK2 Mutation Era

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

[Progress of Study on JAK2V617F Mutation in Myeloproliferative Neoplasm].

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Advances in the Research of JAK2 Abnormalities in Heamatological Disorders

JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Analysis of JAK2V617F and MPLW515L/K Mutation in 30 Patients with Early Stage Myeloproliferative Disease

[Research Progress on Gene Mutation of Jak2].

The Clinical Implications of JAK2V617F Mutation in 137 Chinese Patients with Myeloproliferative Diseases.

Study on JAK2 V617F Point Mutation in 141 Patients with Chronic Myeloproliferatives Diseases

Janus kinase 2 inhibitors in myeloproliferative disorders

[Incidence of JAK2V617F Mutation in Myeloproliferative Diseases and Its Clinical Significance].

Amino Acid Residue E543 in Jak2 C618r is A Potential Therapeutic Target for Myeloproliferative Disorders Caused by Jak2 C618r Mutation

[The Clinical Implication of JAK2 Mutation Expression in Patients with Myeloproliferative Disorders].

[Detection and Clinical Significance of JAK2 Mutation in 412 Patients with Chronic Myeloproliferative Neoplasms].

Research progress of JAK1/2 inhibitors in the treatment of myeloproliferative neoplasms

JAK2 V617F Mutation in BCR-ABL Negative Patients with Myeloproliferative Disorder and Its Clinic Significance

[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].

The relationship of JAK2V617F mutation and clinical characteristics in patients with myeloproliferative Neoplasms

The Overall Analysis of JAK2 and MPL Mutation Status in Chinese MPD Patients by MassARRAY Assay